Advanced Urothelial Carcinoma Clinical Trial
Official title:
A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma
To evaluate the safety and efficacy of recombinant anti-PD-L1 monoclonal antibody injection (ZKAB001) combined with Albumin-bound paclitaxel in the treatment of Advanced urothelial carcinoma
This trial is designed to first include 6 subjects to confirm the dose safety. If the toxicity is intolerable, the dose of chemotherapeutic drugs will be reduced depending on the toxicity for further exploration.If it was tolerated, the recommended dose was determined, and the dose was extended. 14 patients were enrolled to further observe the safety and efficacy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00365157 -
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01487915 -
Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04064190 -
Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
|
Phase 2 | |
| Not yet recruiting |
NCT06079112 -
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05544552 -
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
| Active, not recruiting |
NCT02735252 -
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
|
N/A | |
| Recruiting |
NCT05733000 -
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05738161 -
Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma
|
Phase 1 | |
| Completed |
NCT00942331 -
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT05687721 -
Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04871334 -
Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT06196736 -
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
|
Phase 3 | |
| Completed |
NCT02599324 -
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04491942 -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
|
Phase 1 | |
| Recruiting |
NCT05929235 -
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
|
Phase 1 | |
| Recruiting |
NCT04856189 -
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
|
Phase 1/Phase 2 |